Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 473-478

  Megha, Tiziana ^a   Ferrari, Filomena ^a   Arcuri, Felice ^a   Lalinga, Anna Vittoria ^a   Lazzi, Stefano ^a   Cardone, Concetta ^a   Cevenini, Gabriele ^a   Leoncini, Lorenzo ^a   Tosi, Piero ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

bcl 2; Cell kinetics; Ductal carcinoma in situ; Infiltrating ductal carcinoma; p53

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KINETICS; MIDDLE AGED; MITOSIS INDEX; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, P53; HUMANS; KINETICS; MIDDLE AGED; MITOTIC INDEX; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034181845     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.473     Document Type: Article

References (29)

1. Wyllie AH: The biology of cell death in tumours. Anticancer Res 5: 131-136, 1985.
2. Lipponen P, Aaltomaa S, Kosma VM and Syrianen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A: 2068-2073, 1994.
3. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW and Nicholson RI: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
4. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
5. Lane DP and Benchimol S: P53: oncogene or anti-oncogene? Genes Dev 4: 1-8, 1990.
6. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
7. Lane DP: P53: the guardian of the genome. Nature 358: 15-16, 1992.
8. Miyashita T, Harigai M, Hanada M, et al: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
9. Moll UM, LaQuaglia M, Benard J and Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411, 1995.
10. Malcomson RD, Oren M, Wyllie AH and Harrison DJ: P53-independent death and p53-induccd protection against apoptosis in fibroblast treated with chemotherapeutic drugs. Br J Cancer 72: 952-957, 1995.
11. Iggo R, Gatter K, Bartek J, Lane D and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
12. Davidoff AM, Herndon JE II, Glover NS, Kerns BJ, Pence JC, Iglehart JD, et al: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264, 1991.
13. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al: Mutation in the p53 gene occur in diverse human tumor types. Nature 8: 342-705, 1989.
14. Bartek J, Bartkova J, Vojlesek B, et al: Patterns of expression of the p53 tumour suppressor in human breast tissue and tumours in situ and in vitro. Int J Cancer 46: 839-844, 1990.
15. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW and Ellis IO: P53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24: 463-468, 1992.
16. World Health Organization: Histological typing of breast tumors. International histological classification of tumours. 2nd edition. No. 2. Geneva, 1981.
17. Hermanek P and Sobin LH: UICC International Union Against Cancer. TNM Classification of Malignant Tumors. 4th edition. Springer-Verlag, Berlin, pp93-99, 1987.
18. Leoncini L, Spina D, Close P, Megha T, Pacenti L, Tosi P, Pileri S, De Vivo A, Kraft R, Laissue JA and Cottier H: Abortive mitosis and nuclear fragmentation in CD30+ large cells of Hodgkin's disease. Leuk Lymphoma 22: 119-124, 1996.
19. Spina D, Leoncini L, Megha T, Gallorini M, Tosi P, Pileri S, Kraft R, Laissue JA and Cottier H: Growth patterns of diffuse non-Hodgkin's lymphomas estimated from mitotic and apoptotic indices. Int J Cancer 73: 178-183, 1997.
20. Wright DK and Manos MM: Sample preparation from paraffin-embedded tissues. In: PCR Protocols: a Guide to Methods and Applications. Innis MA, Gelfand DH and Sni JJ (eds). Academic press, 1989.
21. Soong R and Iacopetta BJ: A rapid and nonisotopic method for the screening and sequencing of p53 gene mutation in formalin-fixed, paraffin embedded tumors. Mod Pathol 10: 252-258, 1997.
22. Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJS, Hahnel R and Robbins PD: Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642-647, 1997.
23. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
24. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993.
25. Zha H, Aime-Sempe C, Sato T and Reed JC: Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 271: 7440-7444, 1996.
26. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
27. Yang E, Zha H, Jockel J, Boise LH, Thompson CB and Korsmever SJ: Bad, a heterodimeric partner for Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
28. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD and Barr PJ: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374: 736-739, 1995.
29. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A and Craig RW: Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 54: 6348-6352, 1994.